Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

Amgen Inc. (NASDAQ: AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street’s reaction to the company’s latest data announcement regarding MariTide, ...

In the most recent trading session, Amgen (AMGN) closed at $280.35, indicating a +1.03% shift from the previous trading day.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Investing.com - BMO Capital maintained its Outperform rating and $346.00 price target on Amgen (NASDAQ: AMGN) stock Tuesday following the release of Phase 1 MariTide clinical trial data.According ...

Our dashboard How Low Can Amgen Stock Go In A Market Crash? dives into historical performance across market crashes. Inflation Shock (2022) AMGN dropped 26.7% from $292.39 (8 Nov 2022) to $214.27 ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

To get a sense of who is truly in control of Amgen Inc. (NASDAQ:AMGN), it is important to understand the ownership structure of the business. The group holding the most number of shares in the company ...

View the latest Amgen Inc. (AMG) stock price, news, historical charts, analyst ratings and financial information from WSJ.